JP2025509613A - がん治療のためのMetAP2阻害剤を含む組み合わせ - Google Patents

がん治療のためのMetAP2阻害剤を含む組み合わせ Download PDF

Info

Publication number
JP2025509613A
JP2025509613A JP2024554864A JP2024554864A JP2025509613A JP 2025509613 A JP2025509613 A JP 2025509613A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2025509613 A JP2025509613 A JP 2025509613A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
combination
ceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509613A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ.カーバー ブラッドリー
シャナハン ジェイムズ
コーネリウス ピーター
メイズ ベンジャミン
Original Assignee
シンデブルックス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンデブルックス,インコーポレイティド filed Critical シンデブルックス,インコーポレイティド
Publication of JP2025509613A publication Critical patent/JP2025509613A/ja
Publication of JP2025509613A5 publication Critical patent/JP2025509613A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024554864A 2022-03-16 2023-03-16 がん治療のためのMetAP2阻害剤を含む組み合わせ Pending JP2025509613A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263320347P 2022-03-16 2022-03-16
US63/320,347 2022-03-16
US202263340726P 2022-05-11 2022-05-11
US63/340,726 2022-05-11
PCT/US2023/064550 WO2023178255A1 (en) 2022-03-16 2023-03-16 Combinations comprising metap2 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025509613A true JP2025509613A (ja) 2025-04-11
JP2025509613A5 JP2025509613A5 (cg-RX-API-DMAC7.html) 2026-03-26

Family

ID=85979451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554864A Pending JP2025509613A (ja) 2022-03-16 2023-03-16 がん治療のためのMetAP2阻害剤を含む組み合わせ

Country Status (9)

Country Link
US (1) US20260014194A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493181A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509613A (cg-RX-API-DMAC7.html)
KR (1) KR20240164549A (cg-RX-API-DMAC7.html)
CN (1) CN119300818A (cg-RX-API-DMAC7.html)
AU (1) AU2023235307A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245962A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011197A (cg-RX-API-DMAC7.html)
WO (1) WO2023178255A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021378944A1 (en) * 2020-11-11 2023-06-15 Syndevrx, Inc. Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3177603T3 (en) * 2014-08-04 2019-01-14 Merck Patent Gmbh PYRROLIDINE UNDERIVATIVES AS METAP-2 INHIBITORS
US11612577B2 (en) * 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Also Published As

Publication number Publication date
WO2023178255A9 (en) 2024-09-26
EP4493181A1 (en) 2025-01-22
AU2023235307A1 (en) 2024-10-17
KR20240164549A (ko) 2024-11-19
MX2024011197A (es) 2024-09-18
CN119300818A (zh) 2025-01-10
CA3245962A1 (en) 2023-09-21
WO2023178255A1 (en) 2023-09-21
US20260014194A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
EP2269604B1 (en) Treatment of solid kidney tumours with a rapamycin derivative
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
TW201919615A (zh) 用於治療tnbc的化合物
JP2023501912A (ja) 急性骨髄性白血病の治療のためのdhodh阻害剤を含む組成物
JP2021505571A (ja) 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
JP2021169534A (ja) 化学療法の改善
WO2021180111A1 (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
US11083722B2 (en) Combination therapies for the treatment of breast cancer
JP2024542633A5 (cg-RX-API-DMAC7.html)
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
US20260014194A1 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
Feng et al. Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
JP4522261B2 (ja) ブドウ膜黒色腫の処置
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
TW202519221A (zh) Wee1抑制劑及pkmyt1抑制劑之組合
HK40116611A (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
KR20250006934A (ko) 고형 종양을 치료하기 위한 이중 선택적 pi3k 델타 및 감마 억제제 및/또는 염-유도성 키나제 3 억제제
JP2010111582A (ja) リファンピシンを成分とする肝臓癌治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313